Quoin Pharmaceuticals, Ltd. - 8-K Filing
Quoin Pharmaceuticals announced that the FDA conditionally approved QYLEKI™ as the proposed brand name for QRX003, its investigational treatment for Netherton Syndrome. The pivotal Phase 3 study is expected to begin in H2 2026 with a potential New Drug Application (NDA) filing in 2027. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $QNRX